1 Ref: CK-18-0000-AFD(AC)-L-0022 May 15, 2018 Subject: Clarification on Operating Result and Financial Position for the three-month ended March 31, 2018 Attention: President The Stock Exchange of
/2561 June 19, 2018 Subject: Management’s discussion and analysis of the Company’s operating results for Q1/2018 period To: President The Stock Exchange of Thailand DOD Biotech Public Company Limited
Management Discussion and Analysis, Q2/2018 Page1/4 Ref. IR61/12 10 August 2018 Subject: Management Discussion and Analysis, 2nd Quarter Ending 30 June 2018 To : President Stock Exchange of Thailand
No. 256111002 14 November 2018 Subject: Management Discussion and Analysis for the third quarter ended 30 September 2018 To: President The Stock Exchange of Thailand M Vision Public Company Limited
Subject Management Discussion and Analysis for the second quarter ended 30 June 2020 Attention President The Stock Exchange of Thailand According to the resolution of the Board of Directors of JAS Asset
effectively. Consequently, we recorded Bt5,251mn in revenue, growing 26% YoY. Soften EBITDA from cost pressure AIS EBITDA in FY22 was Bt89,731mn, dropped -1.8%YoY mostly from a surging electricity price and
IP_AC/001/2563 February 24, 2020 Subject Management’ discussion and analysis for the fiscal year ended December 31, 2019 To President The Stock Exchange of Thailand Interpharma Public Company Limited
, 2020 Subject Management’ discussion and analysis for the fiscal year ended December 31, 2019 To President The Stock Exchange of Thailand Interpharma Public Company Limited ( “ the Company” ) would like
in sale revenue from DAIWA's clients. Other Income 5.9 4.1 (30.3%) The main reason was causes from the decreasing income earning from the foreign exchange Total Revenue 219.1 200.5 (8.5%) Cost of sales